108 related articles for article (PubMed ID: 15225616)
1. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
2. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Fujii N
Expert Opin Ther Targets; 2005 Dec; 9(6):1267-82. PubMed ID: 16300475
[TBL] [Abstract][Full Text] [Related]
4. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
6. PET of tumor CXCR4 expression with 4-18F-T140.
Jacobson O; Weiss ID; Kiesewetter DO; Farber JM; Chen X
J Nucl Med; 2010 Nov; 51(11):1796-804. PubMed ID: 20956475
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of CXCR4 affect the migration and fate of CXCR4+ progenitors in the developing limb of chick embryos.
Yusuf F; Rehimi R; Moroşan-Puopolo G; Dai F; Zhang X; Brand-Saberi B
Dev Dyn; 2006 Nov; 235(11):3007-15. PubMed ID: 16958136
[TBL] [Abstract][Full Text] [Related]
8. A future perspective on the development of chemokine receptor CXCR4 antagonists.
Tamamura H; Tsutsumi H; Nomura W; Tanaka T; Fujii N
Expert Opin Drug Discov; 2008 Oct; 3(10):1155-66. PubMed ID: 23489074
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists.
Tamamura H; Hiramatsu K; Mizumoto M; Ueda S; Kusano S; Terakubo S; Akamatsu M; Yamamoto N; Trent JO; Wang Z; Peiper SC; Nakashima H; Otaka A; Fujii N
Org Biomol Chem; 2003 Nov; 1(21):3663-9. PubMed ID: 14649897
[TBL] [Abstract][Full Text] [Related]
10. The study of targeted blocking SDF-1/CXCR4 signaling pathway with three antagonists on MMPs, type II collagen, and aggrecan levels in articular cartilage of guinea pigs.
Wang G; Li Y; Meng X; Yang X; Xiang Y
J Orthop Surg Res; 2020 May; 15(1):195. PubMed ID: 32471458
[TBL] [Abstract][Full Text] [Related]
11. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
12. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.
Boulais PE; Dulude D; Cabana J; Heveker N; Escher E; Lavigne P; Leduc R
Biochem Pharmacol; 2009 Dec; 78(11):1382-90. PubMed ID: 19631193
[TBL] [Abstract][Full Text] [Related]
13. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
15. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
16. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice.
Blades MC; Ingegnoli F; Wheller SK; Manzo A; Wahid S; Panayi GS; Perretti M; Pitzalis C
Arthritis Rheum; 2002 Mar; 46(3):824-36. PubMed ID: 11920421
[TBL] [Abstract][Full Text] [Related]
17. Improvement of CXCR4 tracer specificity for PET imaging.
Jacobson O; Weiss ID; Szajek LP; Niu G; Ma Y; Kiesewetter DO; Peled A; Eden HS; Farber JM; Chen X
J Control Release; 2012 Jan; 157(2):216-23. PubMed ID: 21964282
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue.
Bradfield PF; Amft N; Vernon-Wilson E; Exley AE; Parsonage G; Rainger GE; Nash GB; Thomas AM; Simmons DL; Salmon M; Buckley CD
Arthritis Rheum; 2003 Sep; 48(9):2472-82. PubMed ID: 13130466
[TBL] [Abstract][Full Text] [Related]
19. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
Tamamura H; Omagari A; Hiramatsu K; Gotoh K; Kanamoto T; Xu Y; Kodama E; Matsuoka M; Hattori T; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Jul; 11(14):1897-902. PubMed ID: 11459656
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
Tamamura H; Hiramatsu K; Miyamoto K; Omagari A; Oishi S; Nakashima H; Yamamoto N; Kuroda Y; Nakagawa T; Otaka A; Fujii N
Bioorg Med Chem Lett; 2002 Mar; 12(6):923-8. PubMed ID: 11958995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
